Make ABN Newswire your homepage | Add to Favourites
 CHINESE SIMPLE   CHINESE TRAD     JAPANESE     KOREAN
 ENGLISH    ARABIC    EUROPE
 
  Home    |   Media Partners    |    About Us   |   Contact Us
 
Home News
 

Sydney, May 16, 2006 (ABN Newswire) - PRIMA BIOMED LTD (ASX: PRR) - Interim Results - Clinical Trial for Ovarian Cancer Drug; Mr Eugene Kopp, Executive Chairman; Boardroomradio is pleased to announce that PRIMA BIOMED LTD (ASX: PRR) has published an audio file. The following presentation "PRR - Interim Results - Clinical Trial for Ovarian Cancer Drug" is now available as an instant audio download to your computer. You may also transfer this information to your listening device as an IPod podcast.

The BRR service is based on streaming audio sent in compressed form over the internet and displayed as it arrives. You do not have to wait for the whole file to be downloaded before you can hear it, instead the media is sent in a continuous stream and is played immediately as it reaches your computer. Please note that during live broadcasts there can be a delay of approximately 1-2 minutes, depending on traffic through your Internet Service Provider.

Broadcaster: PRIMA BIOMED LTD (ASX: PRR)

Broadcast Title: PRR - Interim Results - Clinical Trial for Ovarian Cancer Drug

Broadcast Type: Audio stream

View the Audio stream for PRIMA BIOMED LTD (ASX: PRR) by clicking on the following links.

Display in Windows Media Player
http://www.boardroomradio.com/event/PRR/1293/11157/wmp/221.242.254.150/wsl.wmp?

or:

Display in MP3 Player or Transfer to Portable Podcast Device
http://www.boardroomradio.com/event/PRR/1293/11157/mp3/221.242.254.150/wsl.mp3?

Computers set up for access to the Internet, including at least a 28.8k modem and sufficient memory and hard disk space to run Windows Media Player or Real Player, should be able to run BRR media files.



About PRIMA BIOMED LTD

Prima Biomed (ASX: PRR) is a biotechnology company based in Sydney, Australia. The Company is focused on technologies in the fields of immunology and cancer immunotherapy. Prima is focused on developing a dendritic-cell based immunotherapy targeting mucin-1 tumour expressed antigen. Prima's lead product, CVac(tm) has completed Phase IIa clinical development in Ovarian Cancer and is working to a path of US FDA IND approval.

About Boardroomradio

Sydney-based Boardroomradio (BRR) is an Investor Relations multi-media portal delivering audio webcasts to the investment community, including brokers, fund managers, analysts, and private investors.



  Related Companies

>>> PRIMA BIOMED LTD
>>> Boardroomradio

 

 
 
PRIMA BIOMED LTD  ASX: PRR - Interim Results - Clinical Trial for Ovarian Cancer Drug; Mr Eugene Kopp, Executive Chairman
 
PRIMA BIOMED LTD
2008.03.19  14:18
Prima Biomed (ASX:PRR) Receives GAP Report For Cancer Product Toward US FDA

2006.05.16  14:00 PRIMA BIOMED LTD Audio WebCast 
PRIMA BIOMED LTD ASX: PRR - Interim Results - Clinical Trial for Ovarian Cancer Drug; Dr George Mihaly, Chair of Scientific Advisory Panel

 
Boardroomradio
2007.05.25  14:52 Boardroomradio Audio WebCast 
Herald Resources Limited ASX: HER - Dairi Project Update - Mr Michael Wright, Executive Director

2007.05.25  14:16 Boardroomradio Audio WebCast 
Albidon Limited ASX: ALB - 2007 AGM Wrap Up - Mr Dale Rogers, MD

2007.05.25  13:13 Boardroomradio Audio WebCast 
Rusina Mining Nl ASX: RML - Philippines Exploration Update - Mr Rob Gregory, MD and CEO

2007.05.25  09:10 Boardroomradio Audio WebCast 
E-pay Asia Limited ASX: EPY - Annual General Meeting 2007 - Mr Michael Lee, Chairman and Dato' Hassan HJ. Said, Executive Director

2007.05.25  08:16 Boardroomradio Audio WebCast 
Essa Australia Limited ASX: ESS - Earnings Upgrade - Mr Darryl Stevens, CEO

 
Asia Business News
Submit Press
News Alerts by Email
Home | Contact Us | About Us
Copyright 2008 Asia Business News Ltd.